HIK Share Price

Open 1710.00 Change Price %
High 1710.00 1 Day -5.00 -0.29
Low 1674.00 1 Week 25.00 1.50
Close 1697.00 1 Month 41.00 2.48
Volume 493208 1 Year -462.00 -21.40
52 Week High 2703.00
52 Week Low 1575.00
HIK Important Levels
Resistance 2 1730.37
Resistance 1 1716.62
Pivot 1693.67
Support 1 1677.38
Support 2 1663.63
LON UK Most Active Stocks
LGO 0.14 0.00%
LGO 0.14 0.00%
LGO 0.14 0.00%
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
LLOY 62.56 0.47%
GKP 1.30 7.44%
FCR 0.25 -10.71%
More..
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
BAF 105.00 133.33%
BAF 105.00 133.33%
BAF 105.00 133.33%
MES 0.28 75.00%
MES 0.28 75.00%
MES 0.28 75.00%
PFLM 5.75 64.29%
BAC 22.87 63.36%
More..
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
BHR 0.02 -33.33%
NBR 0.25 -24.24%
More..

Hikma Pharmaceuticals PLC (LON: HIK)

HIK Technical Analysis 5
As on 8th Dec 2016 HIK Share Price closed @ 1697.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2093.98 & Strong Sell for SHORT-TERM with Stoploss of 1828.45 we also expect STOCK to react on Following IMPORTANT LEVELS.
HIK Target for December
1st Target up-side 1826.66
2nd Target up-side 1915.66
3rd Target up-side 2004.67
1st Target down-side 1572.69
2nd Target down-side 1483.68
3rd Target down-side 1394.67
HIK Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.hikma.com
HIK Address
HIK
13 Hanover Square
London, W1S 1HW
United Kingdom
Phone: 44 20 7399 2760
Fax: 44 20 7399 2761
Interactive Technical Analysis Chart Hikma Pharmaceuticals PLC ( HIK LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Hikma Pharmaceuticals PLC
HIK Business Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms in the Middle East and North Africa, the United States, and Europe. It operates through three segments: Branded, Injectable, and Generic. The Branded segment offers 499 products in 1,256 dosage strengths and forms, which lie in the anti-infective, cardiovascular, central nervous system (CNS), and diabetes therapeutic areas. The Injectables segment markets 200 branded and non-branded products in 379 dosage strengths and forms with a focus on CNS, anti-infective, musculoskeletal, cardiovascular, and oncological therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. The Generics segment provides 11 products in 44 dosage strengths and forms for various therapeutic areas including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory, hormonal, and others. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. In addition, the company offers anesthetics, anti-histamines, gastroenterology and metabolism, dermatology, genitourinary system, transplantation, vitamins and supplements, and miscellaneous products. Further, it manufactures plastic specialized medicinal sterile containers and API; and conducts bio-equivalency studies. The company was founded in 1978 and is based in London, the United Kingdom.